Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Healthcare Medical Devices
Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > The Next Evolution in Health: see Ventripoint
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(91)
•••
Comment by jopatcloon Jun 12, 2024 10:42pm
48 Views
Post# 36086330

RE:The Next Evolution in Health: see Ventripoint

RE:The Next Evolution in Health: see Ventripoint
  • Hugh MacNaught, President and CEO, Ventripoint Diagnostics Limited
1:00 PM

Presentation:

  • Will Hsiao, Faculty of Health Sciences, SFU & affiliated scientist at BC Centre for 

Disease Control & Michael Smith Genome Sciences Centre

‍

1:20 PM

Panel : Accelerating AI Startups in Canadian Health Care

BC is developing applications of AI and digital health with global impact. How can we accelerate the growth of these firms at the same time as we use AI to improve health services in Canada?

  • Maryam Sadeghi, CEO & Co-Founder, MetaOptima
  • Lloyd Jura, Professor, New York Institute of Technology
  • Hugh MacNaught, President and CEO, Ventripoint Diagnostics Limited
  • Tiffany Chui, Vice President, Communications, AbCellera‍
    • Panel moderator: Dr. Alexandra T Greenhill, CEO, CareTeam Technologies
2:00 PM

Event Close

HUGH MACNAUGHT

President and CEO,
Ventripoint Diagnostics Limited

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities